Mayo Clinic — Rochester, MN)
Dr. Rajkumar is the Chairperson of the Board of the International Myeloma Foundation. He is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair of the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He is also Chair of the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee.
Dr. Rajkumar is the recipient of the 2016 Robert A. Kyle Lifetime Achievement Award. He has published more than 230 peer-reviewed papers primarily in the field of multiple myeloma and related plasma cell disorders. He is the Section Editor for multiple myeloma and related disorders for Leukemia and is an Associate Editor for the Mayo Clinic Proceedings.
(University Hospital of Nantes — Nantes, France)
Dr. Moreau is a Professor of Clinical Hematology and Head of the Hematology Department at the University Hospital of Nantes in Nantes, France. He specializes in clinical hematology, particularly focusing on multiple myeloma and treatments with high-dose therapy and novel agents.
Dr. Moreau is the current president of the International Myeloma Society (IMS) and a Scientific Committee Member and Steering Committee Member of the International Myeloma Working Group (IMWG). He is also a current member of the administration council of the Intergroupe Francophone du Myélome (IFM).
With more than 250 peer-reviewed articles and reviews, Dr. Moreau has been widely published in the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, and Blood, to name a few. He is the recipient of the 2018 Robert A. Kyle Lifetime Achievement Award. Dr. Moreau is a member of the Editorial Board of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal. He is also an often-invited speaker at international hematologic oncology meetings.
(Dana-Farber Cancer Institute — Boston, MA)
Dr. Munshi is Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center; Director of the Multiple Myeloma Immune Effector Cell Therapy; a Professor of Medicine at Harvard Medical School; Kraft Family Chair; and a Scientific Committee Member of the International Myeloma Working Group (IMWG).
He earned his MD in 1984 from the Maharaja Sayjirao University in India and completed his postgraduate training in Internal Medicine SSG Hospital and Maharaja Sayjirao University. Additionally, Dr. Munshi has received fellowships at Johns Hopkins Oncology Center and Indiana University Medical Center. He joined the Dana-Farber Cancer Institute in 2001.
Dr. Munshi is the recipient of the 2021 Robert A. Kyle Lifetime Achievement Award.
(University of Navarra — Pamplona, Spain)
Dr. San Miguel is a Professor of Medicine-Haematology and Head of Clinical and Translational Medicine at the University of Navarra in Pamplona, Spain. He is the Medical Director and Vice-Dean of Research at the Clinica Universidad de Navarra; CIMA Scientific Director; a Scientific Committee Member of the International Myeloma Working Group (IMWG).
Dr. San Miguel is the recipient of the 2012 Robert A. Kyle Lifetime Achievement Award. His other accolades include the Waldenstöm Award, EBMT Lecture, Jose Carreras EHA Award, Ham-Wasserman Lecture Award, Rey Jaime I Award in Clinical Medicine, and the Spanish Prizes in both oncology and translational research.
He has had over 700 original papers published in international journals and has made significant contributions to myeloma cell biology and myeloma research in areas such as immunophenotyping, risk of progression from monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma into active myeloma, and minimal residual disease (MRD).
Dr. San Miguel has also contributed important studies for new antimyeloma drugs at the preclinical and clinical levels, including proteasome inhibitors, immunomodulatory drugs, and histone deacetylases.